These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21562993)

  • 1. Cost-effectiveness of staff and workload profiles in retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa.
    Vella V; Govender T; Dlamini SS; Moodley I; David V; Taylor M; Jinabhai CC
    AIDS Care; 2011 Sep; 23(9):1146-53. PubMed ID: 21562993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
    Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
    Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa.
    Rosen S; Long L; Sanne I
    Trop Med Int Health; 2008 Aug; 13(8):1005-15. PubMed ID: 18631314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral treatment and the health workforce in South Africa: how have ART workers been affected by scaling up?
    Tobi P; George G; Schmidt E; Renton A
    Trop Med Int Health; 2008 Dec; 13(12):1452-8. PubMed ID: 18983271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
    AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
    Bachmann MO
    AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and outcomes of paediatric antiretroviral treatment in South Africa.
    Meyer-Rath G; Brennan A; Long L; Ndibongo B; Technau K; Moultrie H; Fairlie L; Coovadia A; Rosen S
    AIDS; 2013 Jan; 27(2):243-50. PubMed ID: 23014517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing efficiency and costs of scaling up HIV treatment.
    Cleary SM; McIntyre D; Boulle AM
    AIDS; 2008 Jul; 22 Suppl 1():S35-42. PubMed ID: 18664951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective study on the critical factors for retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa.
    Vella V; Govender T; Dlamini S; Taylor M; Moodley I; David V; Jinabhai C
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):109-16. PubMed ID: 20595904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provision of bednets and water filters to delay HIV-1 progression: cost-effectiveness analysis of a Kenyan multisite study.
    Kern E; Verguet S; Yuhas K; Odhiambo FH; Kahn JG; Walson J
    Trop Med Int Health; 2013 Aug; 18(8):916-24. PubMed ID: 23659539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis.
    Dowdy DW; Sweat MD; Holtgrave DR
    AIDS; 2006 Oct; 20(16):2091-8. PubMed ID: 17053355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi.
    Renaud A; Basenya O; de Borman N; Greindl I; Meyer-Rath G
    AIDS Care; 2009 Nov; 21(11):1388-94. PubMed ID: 20024715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Costs and adherence to antiretroviral treatment].
    Ventura-Cerdá JM; Ayago-Flores D; Vicente-Escrig E; Mollá-Cantavella S; Alós-Almiñana M
    Farm Hosp; 2010; 34(6):284-92. PubMed ID: 20692861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financial and economic costs of scaling up the provision of HAART to HIV-infected health care workers in KwaZulu-Natal.
    Deghaye N; Pawinski RA; Desmond C
    S Afr Med J; 2006 Feb; 96(2):140-3. PubMed ID: 16532083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.